Objective: To investigate the clinical effect of TGP on bone destruction in patients with Rheumatoid Arthritis (RA) by musculoskeletal ultrasound. Methods: A total of 56 patients with rheumatoid arthritis who were admitted to our hospital from 2021-07 to 2023-07 and were randomly divided into the treatment group and the control group with 28 patients in each group according to the random number table method. The control group was treated with methotrexate, and the treatment group was treated with methotrexate and TGP for 12 weeks. Inflammatory indicators such as ESR and CRP were observed before and after treatment. The Clinical effect of the two groups was evaluated by ACR20/50/70. Musculoskeletal ultrasound was used to detect synovial, the synovium blood flow signal, bone erosion and joint effusion. The above indexes were compared between the two groups before and after treatment. Results: ① The control rate of ACR20/50/70 in the treatment group was higher than that in the control group, and the inflammatory indexes ESR and CRP in both groups were lower than before treatment, but the treatment group was significantly higher than the control group. ② Compared with before treatment, synovial, articular effusion and synovial blood flow were all decreased in 2 groups, and the decrease was more obvious in the treatment group, the difference was statistically significant, while there was no statistically significant difference in bone destruction before and after treatment. Conclusion：TGP can improve the standard reaching rate, reduce the symptoms of patients with rheumatoid arthritis in the acute phase, inhibit inflammatory response, protect joints, prevent RA bone damage, and delay the progression of rheumatoid arthritis.